Literature DB >> 28779372

Erythropoietin Attenuates Cardiac Dysfunction in Rats by Inhibiting Endoplasmic Reticulum Stress-Induced Diabetic Cardiomyopathy.

Jing Lu1, Qi-Ming Dai1, Gen-Shan Ma1, Yue-Hong Zhu1, Bing Chen1, Bing Li1, Yu-Yu Yao2.   

Abstract

PURPOSE: Enhanced endoplasmic reticulum (ER) stress and down-regulated SERCA2a expression play crucial roles in diabetes. We aimed to verify whether erythropoietin (EPO) attenuates cardiac dysfunction by suppressing ER stress in diabetic rats.
METHODS: Forty male SD rats were randomly divided into four groups: control, EPO-treated control, vehicle-treated diabetic, and EPO-treated diabetic groups. The animals in the EPO-treated control and diabetic groups were administered recombinant human EPO (1000 U/kg body weight) once per week for 12 weeks. RT-PCR and Western blotting assays were performed to detect the expression of 78-kDa glucose-regulated protein precursor (GRP78) and sarcoplasmic/endoplasmic reticulum Ca2+-ATPase (SERCA2a). We cultured neonatal rat cardiomyocytes and investigated the protective effects of EPO against high glucose (HG)-induced apoptosis. Intracellular calcium levels were measured through confocal microscopy.
RESULTS: We observed increased myocardial GRP78 expression and decreased myocardial SERCA2a expression in diabetic rats. EPO prevented the changes in GRP78, SERCA2a expression and cardiac dysfunction in diabetic rats. The levels of GRP78 protein were significantly reduced in EPO-treated diabetic rats compared with vehicle-treated diabetic rats (GRP78 protein 0.09 ± 0.03 vs. 0.54 ± 0.04, P < 0.01). The levels of the SERCA2a proteins were significantly increased in EPO-treated diabetic rats compared with vehicle-treated diabetic rats (SERCA2a protein 0.60 ± 0.05 vs. 0.13 ± 0.04, P < 0.01). A reduction in apoptosis was observed in the cardiomyocytes treated with 20 U/mL EPO compared with the cardiomyocytes cultured under HG conditions (apoptosis rate 18.9 ± 1.94 vs. 37.9 ± 1.59%, P < 0.01).
CONCLUSIONS: This study demonstrates that EPO treatment improved the parameters of cardiac function following HG-induced injury by suppressing ER stress and inducing SERCA2a expression.

Entities:  

Keywords:  Cardiomyocyte apoptosis; Diabetes mellitus; Endoplasmic reticulum stress; Erythropoietin; SERCA2a

Mesh:

Substances:

Year:  2017        PMID: 28779372     DOI: 10.1007/s10557-017-6742-1

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  4 in total

1.  Associations between erythropoietin polymorphisms and risk of diabetic microvascular complications.

Authors:  Hua Li; Huipu Xu; Yuerong Li; Dongdong Zhao; Baoxin Ma
Journal:  Oncotarget       Date:  2017-11-27

2.  Repetitive Neonatal Erythropoietin and Melatonin Combinatorial Treatment Provides Sustained Repair of Functional Deficits in a Rat Model of Cerebral Palsy.

Authors:  Lauren L Jantzie; Akosua Y Oppong; Fatu S Conteh; Tracylyn R Yellowhair; Joshua Kim; Gabrielle Fink; Adam R Wolin; Frances J Northington; Shenandoah Robinson
Journal:  Front Neurol       Date:  2018-04-13       Impact factor: 4.003

3.  Erythropoietin suppresses hepatic steatosis and obesity by inhibiting endoplasmic reticulum stress and upregulating fibroblast growth factor 21.

Authors:  Ting Hong; Zhijuan Ge; Bingjie Zhang; Ran Meng; Dalong Zhu; Yan Bi
Journal:  Int J Mol Med       Date:  2019-05-28       Impact factor: 4.101

4.  The erythropoietin receptor expressed in skeletal muscle is essential for mitochondrial biogenesis and physiological exercise.

Authors:  Kirsten T Nijholt; Laura M G Meems; Willem P T Ruifrok; Alexander H Maass; Salva R Yurista; Mario G Pavez-Giani; Belend Mahmoud; Anouk H G Wolters; Dirk J van Veldhuisen; Wiek H van Gilst; Herman H W Silljé; Rudolf A de Boer; B Daan Westenbrink
Journal:  Pflugers Arch       Date:  2021-06-17       Impact factor: 3.657

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.